Obvious Ventures
VC Fund
San Francisco, United States
Obvious Ventures is a venture capital firm that invests in the early and growth stages. The firm was founded in 2014 and is based in San Francisco, California.
- Total investments:
- 203
- Last investment:
- Lead investor:
- 30%
- Fund size:
- $360M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Obvious Ventures invests in
Stages Obvious Ventures invests in
Countries Obvious Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Seed
- $2M–$13M
- Series A
- $5M–$42M
- Series B
- $15M–$150M
Investment Focus
Industry
- Software 21 (10%)
- Health Care 17 (8%)
- Artificial Intelligence 15 (7%)
- Biotechnology 11 (5%)
- Medical 8 (4%)
Stage
- Series A 56 (28%)
- Series B 36 (18%)
- Seed 31 (15%)
- Series C 13 (6%)
- Funding Round 7 (3%)
Country
- United States 82 (40%)
- Canada 4 (2%)
- Germany 2 (1%)
- United Kingdom 2 (1%)
- France 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
André Heinz
Venture Partner
|
Venture Partner | Total investments: 2 | Find email | |
James Joaquin
Co-Founder and Managing Director
|
Co-Founder and Managing Director | Total investments: 31 | Find email | |
Andrew Beebe
Managing Director
|
Managing Director | Total investments: 18 | Find email | |
Chris Cheng
Senior Associate
|
Senior Associate | Total investments: 0 | Find email | |
Di-Ann Eisnor
Venture Partner
|
Venture Partner | Total investments: 3 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| GenHealth.ai provides healthcare solutions using generative AI trained on encoded medical events. Its product is a generative healthcare AI publicly available. It includes a foundation transformer model (new neural networks with excellent memory), an API, and user applications that can generate and predict future sequences of health events usinghistorical events. Together they can be used to build a large variety of customized applications. | $16.5M / Series A / Sep 08, 2026 | ||
| Gritt Robotics is automating renewable energy construction using AI and Robotics. | $26M / Series A / Jul 21, 2026 | ||
| Hostie is an AI-first customer experience platform designed for restaurants, automating guest inquiries, reservations, and takeout orders. We proudly partner with some of the world’s top restaurants, including Flour + Water, Nisei, Slanted Door, ILIS, and more. Co-founded by a product designer-turned-restaurateur and an AI engineer, Hostie blendshospitality expertise with cutting-edge technology to enhance restaurant operations. | $12M / Series A / Jul 08, 2026 | ||
| Radical Numerics develops a unified AI model that comprehensively understands and generates biological data, integrating DNA, RNA, proteins, and all molecular components of living systems into a single framework. The company is known for its Evo and Evo 2 models, which are large biological AI models that have been trained on extensive DNAsequences. | $50M / Seed / Jun 15, 2026 | ||
| Gray Swan AI is an AI security company that develops tools for evaluating and protecting large language model deployments. Its platform focuses on identifying vulnerabilities such as jailbreaks, prompt injections, harmful outputs, and other adversarial attacks that can affect AI systems in production. The company offers products including Shade, anautomated red-teaming and vulnerability assessment tool, and Cygnal, a runtime protection layer that monitors and filters AI interactions in real time. Gray Swan’s technology is designed to work with multiple AI providers and is used to test the security and reliability of AI applications, agents, and workflows. The company also operates adversarial testing programs and collaborates with AI researchers and enterprises to study emerging threats and improve AI safety practices. | $40M / Series A / May 28, 2026 | ||
| Iterative Health is a healthcare technology and services company that focuses on accelerating clinical research to improve patient outcomes through innovative approaches. The company transforms gastrointestinal (GI) care by utilizing AI-driven clinical trials and diagnostics, significantly enhancing access to vital treatments. | $77M / Series C / Apr 30, 2026 | ||
| Halcyon provides an AI-assisted search and information platform to navigate energy transition decision-making for investors and analysts. | $21M / Series A / Mar 16, 2026 | ||
| Zanskar develops a predictive platform informed by massive data for discovering previously unknown geothermal resources. Its platform includes subsurface characterization technology and massive data sets, enhancing and reducing risk in the exploration of geothermal resources. | $115M / Series C / Jan 21, 2026 | ||
| Fleetzero is building battery electric cargo ships to affordably decarbonize ocean freight. | $43M / Series A / Jan 16, 2026 | ||
| Boltz, PBC is a public-benefit AI research company whose mission is to enable every scientist to reshape biology and create a healthier, more sustainable future. Its state-of-the-art AI models are used by leading pharmaceutical and biotech companies for biomolecular structure prediction, affinity estimation, and generative design across multiplemodalities. | $28M / Seed / Jan 08, 2026 | ||
| See all 203 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Obvious Ventures invest in?
Obvious Ventures invests primarily in Software, Health Care and Artificial Intelligence startups, most often at Series A and Series B stage. Most of the 203 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Obvious Ventures's check size?
Obvious Ventures typically joins rounds of $2M–$13M at Seed, $5M–$42M at Series A and $15M–$150M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Obvious Ventures participates in.
How do I contact Obvious Ventures?
Public channels for Obvious Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Obvious Ventures?
The team at Obvious Ventures includes André Heinz (Venture Partner), James Joaquin (Co-Founder and Managing Director) and Andrew Beebe (Managing Director), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
